Nanoparticle pharmacokinetic profiling in vivo using magnetic resonance imaging.

Research paper by Anne M AM Neubauer, Hoon H Sim, Patrick M PM Winter, Shelton D SD Caruthers, Todd A TA Williams, J David JD Robertson, David D Sept, Gregory M GM Lanza, Samuel A SA Wickline

Indexed on: 26 Nov '08Published on: 26 Nov '08Published in: Magnetic Resonance in Medicine


Contrast agents targeted to molecular markers of disease are currently being developed with the goal of identifying disease early and evaluating treatment effectiveness using noninvasive imaging modalities such as MRI. Pharmacokinetic profiling of the binding of targeted contrast agents, while theoretically possible with MRI, has thus far only been demonstrated with more sensitive imaging techniques. Paramagnetic liquid perfluorocarbon nanoparticles were formulated to target alpha(v)beta(3)-integrins associated with early atherosclerosis in cholesterol-fed rabbits to produce a measurable signal increase on magnetic resonance images after binding. In this work, we combine quantitative information of the in vivo binding of this agent over time obtained by means of MRI with blood sampling to derive pharmacokinetic parameters using simultaneous and individual fitting of the data to a three compartment model. A doubling of tissue exposure (or area under the curve) is obtained with targeted as compared to control nanoparticles, and key parameter differences are discovered that may aid in development of models for targeted drug delivery.

More like this: